acorda
-
Acorda Therapeutics Announces Filing of Patent Extension Applications for AMPYRA(TM) (dalfampridine)
HAWTHORNE, N.Y., Mar 22, 2010 (BUSINESS WIRE) — Acorda Therapeutics, Inc. (ACOR 34.95, +0.11, +0.32%)today announced that the Company has submitted applications to…
Read More » -
Acorda Therapeutics Announces Adrian L. Rabinowicz Joins as Senior Vice President of Medical Affairs
HAWTHORNE, N.Y., Feb 22, 2010 (BUSINESS WIRE) — Acorda Therapeutics, Inc. (ACOR 31.71, -0.23, -0.72%)announced today that Adrian L. Rabinowicz, M.D., FAAN, has…
Read More » -
Acorda Therapeutics Announces Lauren Sabella Joins as Executive Vice President of Commercial Development
HAWTHORNE, N.Y.–(BUSINESS WIRE)–Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced today that Lauren Sabella has joined the Company as Executive Vice President,…
Read More » -
Acorda Therapeutics to Present at the 28th Annual JPMorgan Healthcare Conference
HAWTHORNE, N.Y.–(BUSINESS WIRE)–Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Ron Cohen, M.D., President & CEO, will present at the…
Read More »